Clinical Trial Update: Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke. [Phase 1, Phase 2]

View source ↗

Summary

This update summarizes the completion of a Phase 1/2 safety study evaluating a recombinant human plasminogen activator for the treatment of acute ischemic strok…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Recombinant human plasminogen activator (tissue plasminogen activator (rt-PA))

Snippet

Sponsor: Global Biotech | Conditions: Cerebrovascular Accident | Phase 1, Phase 2 | Status: COMPLETED